HENGRUI PHARMA: 2025 INTERIM REPORT

Hengrui Pharma achieved operating revenue of RMB 15.761 billion in the first half of 2025, representing a year-on-year increase of 15.9%; net profit attributable to parent company shareholders reached RMB 4.450 billion, up 29.7% year-on-year. Revenue from innovative drug sales amounted to RMB 7.570 billion, with licensing income at RMB 1.991 billion, collectively accounting for 60.7% of total revenue. The gross margin during the period was 86.6%, net margin was 28.3%, and net cash flow from operating activities was RMB 4.300 billion, registering a year-on-year increase of 41.8%.During the reporting period, the company invested RMB 3.871 billion in R&D, including RMB 3.228 billion in R&D expenses. Six new Class 1 innovative drugs were approved for marketing, including Recombinant Trastuzumab, Famitinib, Fosaprepitant Pamoate Palonosetron, among others; six...Show More

Hengrui Pharma achieved operating revenue of RMB 15.761 billion in the first half of 2025, representing a year-on-year increase of 15.9%; net profit attributable to parent company shareholders reached RMB 4.450 billion, up 29.7% year-on-year. Revenue from innovative drug sales amounted to RMB 7.570 billion, with licensing income at RMB 1.991 billion, collectively accounting for 60.7% of total revenue. The gross margin during the period was 86.6%, net margin was 28.3%, and net cash flow from operating activities was RMB 4.300 billion, registering a year-on-year increase of 41.8%.During the reporting period, the company invested RMB 3.871 billion in R&D, including RMB 3.228 billion in R&D expenses. Six new Class 1 innovative drugs were approved for marketing, including Recombinant Trastuzumab, Famitinib, Fosaprepitant Pamoate Palonosetron, among others; six new indications were also approved. Agreements were reached with Merck Sharp & Dohme and IDEAYA Biosciences, securing upfront payments of USD 200 million and USD 75 million, respectively.The company continues to strengthen its innovation efforts, with its commercial network covering over 25,000 hospitals and 200,000 offline retail pharmacies across more than 30 provincial administrative regions in China. As of the end of the reporting period, 15 novel molecules entered clinical trials for the first time, spanning multiple therapeutic areas such as oncology, metabolic and cardiovascular diseases, immunology, and respiratory conditions. The company's ADC platform has advanced over 10 new molecules into clinical trials, with Recombinant Trastuzumab having nine indications designated as breakthrough therapies.